~/8 T cells can be grouped into discrete subsets based upon their expression of T cell receptor (TCR) variable (V) region families, their tissue distribution, and their specificity. V~2 + T cells constitute the majority of~/8 T cells in peripheral blood whereas V81 + T cells reside preferentially in skin epithelium and in the intestine. ~/~ T cells are envisioned as first hne host defense mechanisms capable of providing a source of immune effector T cells and immunomodulating cytokines such as interleukin (IL) 4 or interferon (IFN) % We describe here the fine specificity of three distinct ~/~+ tumor-infiltrating lymphocytes (TIL) obtained from patients with primary or metastatic colorectal cancer, that could be readily expanded in vitro in the presence oflL-l~ and IL-7. Irrespective of donor, these individual ~/8 T cells exhibited a similar pattern of reactivity defined by recognition ofautologous and allogeneic colorectal cancer cells, renal cell cancer, pancreatic cancer, and a freshly isolated explant from human intestine as measured by cytolytic T cell responses and by IFN-~/release. In contrast, tumors of akemate histologies were not lysed, including lung cancer, squamous cell cancer, as well as the natural/lymphocyte-activated killer cell-sensitive hematopoietic cell lines T2, CIR, or Daudi. The cell hne K562 was only poorly lysed when compared with colorectal cancer targets. Target cell reactivity mediated by V8I + T cells was partially blocked with Abs directed against the TCR, the [32 or [37 integrin chains, or fibronectin receptor. Marker analysis using flow cytometry revealed that all three ~ T cell lines exhibit a similar phenotype. Analysis of the ~/8 TCR junctional suggested exclusive usage of the V81/D~3/J81 TCtk segments with extensive (~<29 bp) N/P region diversity. T cell recognition of target cells did not appear to be major histocompatibility complex restricted or to be correlated with target cell expression of heat-shock proteins. Based on the ability of some epithehal tumors, including colorectal, pancreatic, and renal cell cancers to effectively cold target inhibit the lysis of colorectal cancer cell lines by these V8I + T cell lines, we suggest that intestinal V~I + T cells are capable of recognizing cell surface Ag(s) shared by tumors of epithehal origin.
Summary
~/8 T cells can be grouped into discrete subsets based upon their expression of T cell receptor (TCR) variable (V) region families, their tissue distribution, and their specificity. V~2 + T cells constitute the majority of~/8 T cells in peripheral blood whereas V81 + T cells reside preferentially in skin epithelium and in the intestine. ~/~ T cells are envisioned as first hne host defense mechanisms capable of providing a source of immune effector T cells and immunomodulating cytokines such as interleukin (IL) 4 or interferon (IFN) % We describe here the fine specificity of three distinct ~/~+ tumor-infiltrating lymphocytes (TIL) obtained from patients with primary or metastatic colorectal cancer, that could be readily expanded in vitro in the presence oflL-l~ and IL-7. Irrespective of donor, these individual ~/8 T cells exhibited a similar pattern of reactivity defined by recognition ofautologous and allogeneic colorectal cancer cells, renal cell cancer, pancreatic cancer, and a freshly isolated explant from human intestine as measured by cytolytic T cell responses and by IFN-~/release. In contrast, tumors of akemate histologies were not lysed, including lung cancer, squamous cell cancer, as well as the natural/lymphocyte-activated killer cell-sensitive hematopoietic cell lines T2, CIR, or Daudi. The cell hne K562 was only poorly lysed when compared with colorectal cancer targets. Target cell reactivity mediated by V8I + T cells was partially blocked with Abs directed against the TCR, the [32 or [37 integrin chains, or fibronectin receptor. Marker analysis using flow cytometry revealed that all three ~ T cell lines exhibit a similar phenotype. Analysis of the ~/8 TCR junctional suggested exclusive usage of the V81/D~3/J81 TCtk segments with extensive (~<29 bp) N/P region diversity. T cell recognition of target cells did not appear to be major histocompatibility complex restricted or to be correlated with target cell expression of heat-shock proteins. Based on the ability of some epithehal tumors, including colorectal, pancreatic, and renal cell cancers to effectively cold target inhibit the lysis of colorectal cancer cell lines by these V8I + T cell lines, we suggest that intestinal V~I + T cells are capable of recognizing cell surface Ag(s) shared by tumors of epithehal origin.
T wo distinct populations of ~/8+ TCK-bearing cells have been previously characterized based on their expression of distinct TCtk V gene segments and their unique tissue distribution. The dominant ~/8+ T cell population in the peripheral circulation is defined by coexpression of the V~2 and the V~/9 TCK (1, 2) segments, constituting 70-90% of the ~/~+ T subsets in PBL, and representing 5-10% of all TCK + peripheral T lymphocytes. A different, far less frequent, ~/8 + T cell population in PBL is detected by the mAb ~TCS-1 (3) recognizing the V81/J81/J~2 TCR (4) . This particular subpopulation constitutes only 5-10% of the ~/8 T cell population in human PBL, but it represents the majority of',/8 T lymphocytes found in the oral and intestinal epithelia (5) (6) (7) (8) (9) . The TCtk V~2/V~/9 predominance in PBL is thought to reflect an Ag-driven expansion potentially involving the superantigen staphylococcal enterotoxin A (10), isopentyl pyrophosphate, and related prenyl pyrophosphate derivates, components ofmycobacterial Ags (11) , or cell-derived proteins expressed upon viral infection (12) . Individual ",/8 T cell clones have been previously reported to recognize MHC class I and II, CDlc Ags, nonclassical minor MHC Ags, or heat--shock proteins (HSPsl; [13] [14] [15] [16] [17] [18] [19] [20] . Extensive analysis of the CDR3 region of the ~/~ TCR (21) suggests that the topology of the interaction of the ~ TCR with MHC Ags is clearly different from that observed for oq3 § T cells, suggesting that the ~/5 TCR may be able to recognize native (i.e., non-MHC presented) protein Ags (12) . This hypothesis implies that Ag recognition by ~/5 + T cells may more closely resemble soluble Ag recognition by Igs, rather than recognition of short peptide fragments presented by MHC molecules to off3 + TCR. cells (12, 19, 20) . Whereas some targets have been identified for V~2 + T cells, the Ags recognized by the V81 + TCR subset are unknown. Exclusive expansion of this particular subset has been observed in a variety of different diseases: V~I § T cells are selectively expanded in vivo in the peripheral blood of patients with EBV or HIV infections (22) (23) (24) . V81 + T cells are also preferentially expanded in the lungs of patients with pulmonary sarcoidosis and in lesions from patients infected with Mycobacterium leprae (25) , in synovial fluid from patients with rheumatoid arthritis (26, 27) , in cerebospinal fluid from patients with acute multiple sclerosis (28, 29) , in intestinal lesions from patients with coelical disease (30, 31) , and in acute or chronic graft rejections in heart transplant patients (32) . Preferential expansion and cytotoxic antitumor responses of the V81 + T cell subset have been demonstrated in patients with tumors of epithelial origin, including adenocarcinomas of the lung (33, 34) and, most recently, in renal cell cancer (35) . Such VB1 TCR + T cells exhibit a characteristic recognition pattern, lysing the autologous and allogeneic cell lines with similar histologies (35) . V~I + T cells lyse, albeit to a lesser extent, the NK-sensitive celt line K562, but not other NK/LAK-sensitive cell lines, and are apparently not MHC restricted (33) (34) (35) . We report the in vitro expansion of three V~I § T cell lines cultured in the presence of IL-1[3 and IL-7 from tumor-infiltrating lymphocytes (TIL) derived from patients with primary or metastatic colorectal cancer. These ~/~ T cell lines appear to recognize common Ag(s) shared by colorectal, renal cell, and pancreatic cancers defined by both cytolytic T cell reactivity and by IFN-'y release. These data suggest that cytotoxic V81 § T cells may be critically involved in immune responses against cancer of epithelial origin in situ.
Materials and Methods
Cell Lines. Target cell lines used in cytotoxicity or cytokine release assays were maintained in [kPMI-1640 supplemented with 10% heat-inactivated fetal bovine serum, 2 mM L-glutamine, 100 IU/ml penicillin, and 100 p~g/ml streptomycin (GIBCO BRL, Gaithersburg, MD; complete medium [CM]) unless otherwise indicated. Short-term cultures of freshly harvested tumor single cell suspensions from colorectal cancer patients were also grown in CM. CIR. or human EBV-transformed B cell lines (S-EBV) expressing the muc 1 molecules have been described previously (36) 1Abbreviations used in this paper: CM, complete medium; HFR, human fibronectin receptor; HVR, human vitronectin receptor; RT, reverse transcriptase; TIL, tumor-infiltrating lymphocyte(s). and were grown in CM supplemented with 600 p.g/ml G418 (GIBCO BRL). The breast cancer cell line BT20 and the cell line U937 (MHC class II negative), its MHC class II-positive subclone I 937, the colorectal cancer cell line DLD-1, the pancreatic cancer cell lines pancreas89 and pancreasQGP9 were kind gifts from Dr. O. Finn (University of Pittsburgh Medical School). The colorectal cancer cell lines LS174 and SW480, the Wilms tumor cell line SKNEP-1, and the explant culture (passage 1) from normal human intestine (CRL7136, HS186.lNT) were obtained from the American Type Culture Collection (ATCC, R.ockville, MD). The colorectal cancer cell lines HCT116 and HT29, the squamous cell cancer cell lines PCI-13 and PCI-50 (head and neck cancer), and target cell lines Daudi, Molt-4, and K562 were kindly provided by Dr. Theresa Whiteside, University of Pittsburgh Cancer Institute. The lung cancer cell lines lung201 and lung89 were obtained from Dr. Steven Dobrowolski (University of Pittsburgh Medical School). The melanoma cell line 526 was kindly provided by Dr. S.A. Rosenberg, (National Cancer Institute). The renal cell cancer cell lines NT1973 and NT1257 and the melanoma cell line Mz18 were kindly provided from Dr. Alex Knuth (Krankenhaus Nordwest, Frankfurt, Germany).
TIL. TIL from patients 1881 (colon adenocarcinoma), 3481 (colon adenocarcinoma) and 7179 (colon adenocarcinoma metastatic to liver) were generated as described previously (37) by mincing freshly harvested tumor, by digestion with collagenase (Sigma Chemical Co., St. Louis, MO), and by centrifugation over a Ficoll gradient. The gradient interface was collected, washed twice, resuspended in AIM-V medium (GIBCO BRL), supplemented with 1,000 IU/rrd rhIL-l[3 and 1,000 IU/ml rhlL-7 (kindly provided by Dr. Michael Widmer, lmmunex, Seattle, WA) and seeded at 5 • 10 s cells/ml in 24-well tissue culture plates. TIL have never been restimulated in vitro with tumor. They were split if the cell number exceeded 1.5 • 106 cells/ml and fed with IL-11B/IL-7 containing AIM-V medium. TIL were tested at various time points after in vitro propagation for the presence of "y5 + T lymphocytes by flow cytometry. ~/8 + TIL were purified by flow cytometric cell sorting using the anti-pan-~/5 TCR mAb TCR51 (clone 5A6.E93; T-Cell Sciences, Cambridge, MA; see Table 1 ) and the FACStar | (Becton Dickinson & Co., Mountain View, CA) and were then expanded in IL-liB/IL-7-containing AIM-V medium over a period of 3 too. Highly purified ~5 + TIL were used at various time points during extended culture as effector T cells in cytotoxicity or cytokine release assays, as indicated. The purity of the respective ~/5 T cell lines was determined by flow cytometric analysis before each experiment. "yS+-sorted TIL lines exhibited a stable "yg+ TCR phenotype (purity >98%) over the 3-too period tested.
Cytolytic Assays. A standard 4-h chromium release assay was used to assess cytolytic recognition of tumor cells by "/5 TIL lines 1881, 3481, and 7279 using an E/T ratio of 5:1 unless otherwise indicated. LAK cells were generated using 7-d 6,000 IU IL-2-stimulated PBL obtained from donor leupacks as control effector cells. SlCr-labeled target cell suspensions were adjusted to 0.5 • 10 s cells/ml and 100 ILl of this cell suspension was added to individual assay wells in triplicate determinations. 100 ILl of TIL effector cells (E/T ratio, 5:1) were then added to experimental wells and plates incubated for 4 h at 37~ Spontaneous release wells received 100 ~1 of TIL medium (AIM-V) and maximum release wells received 100 ~1 of Triton X-100 (10% vol/vol in water). For blocking studies, anti-T cell reagents (mAbs against TCR, anti -132 or -[37 integrin chains, or Abs against the human vitronectin receptor oevl33 (HVR), or the human fibronectin receptor ot5[31 (HFR; see Table 1 ) were used to pretreat effector cells. Cells were seeded in individual assay wells and incubated for 45 rain at 4~ with the respective Ab (10 p,g/104 cells) and the appropriate isotype controls, followed by two washing steps using AIM-V medium. After careful removal of the supernatant, TIL were resnspended in 100 ~zl AIM-V medium supplemented with IL-113 and IL-7 and the appropriate target cell suspensions were added as indicated in 100 ~1. Target single cell suspensions were treated as indicated in blocking experiments using anti-MHC class I and II, anti-CD1, or anti-HSP Abs (see Table 1 ). For cold target inhibition assays, 100 I~1 of the SlCr-labeled target cells was added to individual assay wells along with 100 ~1 of the respective cold target single cell suspension at various dilutions as indicated. T lymphocytes were then added (effector TIL/S1Cr target cells = 5:1) in a volume of 20 ~1 per assay well and a standard 51Cr-release assay was performed twice. 100 I~1 aliquots was harvested from each well and counted in a gamma counter (Pharmacia LKB). R`esults are reported as percent specific chromium release Template cDNA Ppreparation. Total R.NA from 5 X 106 to 5 • 107 cells was extracted from ~/~ TIL lines, from freshly harvested biopsies obtained from colon cancer lesions, or from tumor-free mucosa (adjacent to tumor) obtained from patients undergoing surgery for resection of colorectal cancer at the University of Pittsburgh Medical Center or at the Veterans Administration Hospital (Pittsburgh, PA) using R`NAzol (Biotecx, Inc., Houston, TX) according to the method of Chomczynski and Sacchi (38) . First strand cDNA synthesis was perfomed by heating the reaction at 37~ for 1 h, followed by 5 min at 95~ using a PCR thermal cycler (Perkin-Elmer Corp., Norwalk, CT Amplification of TCR-specific Templates. 150 ng of cDNA was used in each individual PCR` reaction throughout all experiments and the integrity of individual cDNA samples was analyzed using human [3-actin--specific primers (5-3'; forward: ATTTGCG-GTGGACGATGGAGGGGC, backward: GGCATCGTCAC-CAACTGGGACGAC) using the temperature profile 95~ for denaturation, annealing for 1 min at 60~ followed by 1 min at 72~ for extension (30 cycles). The protocol for amplification of V~-or V~/-specific mRNA transcripts was 95~ (2 rain for denaturation) followed by 33 cycles of 94~ (1 rain), 59~ (1 min, 30 s), and 72~ (1 min). The primers sequences for specific V~/ or V~ transcripts have been previously reported elsewhere (28) . Generally, each reaction mixture (50 I~1 vol) contained 25 Ixl H20, 5 Ixl PCR` 10X reaction buffer (Perkin-Elmer Co.), 8 ~1 dNTP (concentration, 1.25 mM each), 5 Ixl of each primer (final concentration, 50 pmol each primer), 1.5 txl cDNA (150 ng), and 1 Ixl Taq-polymerase (Perkin-Elmer Corp.). The respective PCR. reactions were run on 1.5% ethidium bromide-stained agarose gels.
In each PCR. run, a positive control (cDNA from heat-killed Mycobacterium tuberculosis-stimulated PBL) and a negative control (PCI~ mastermix without template cDNA) were included. Primers were synthesized at the DNA Synthesis Facility, University of Pittsburgh. The identity of individual PCP,, products was confinned by Southern blot using internal V'y-or V~-specific primers (data not shown).
Sequencing of V81 + PCR Products. V~I + PCR products gen-
erated from in vitro-cultured (>98% pure) ~+ T cell lines were purified from agarose gels using microfilters obtained from Millipore Corp. (Bedford, MA) and subcloned into the TA cloning vector obtained from Invitrogen (San Diego, CA). Positive clones were randomly selected from each individual "y8 TIL line and sequenced using the ABI system (Applied Biosystems, Foster City, CA) at the University of Pittsburgh DNA sequencing facility.
Results

Colorectal Cancer-derived "1'3 T Cells Expanded in IL-l[3 and IL-7 Exclusively Express the V81 TCR Segment and Preferentially Coexpress the V~/2 TCR.
Tumor-infiltrating T lymphocytes were obtained from three patients with colorectal cancer (patients 1881: primary colon adenocarcinoma; 3481: primary colon adenocarcinoma; 7279: colon adenocarcinoma metastatic to the liver) and were cultured for 6 wk in IL-113 and IL-7 (1,000 IU/ml each) containing AIM-V medium. Phenotypic analysis of individual (bulk) cultures performed at day 54 revealed 10-48% CD3+/2t~+/V~I + positive-staining T cells (data not shown). ~/~+ T cells were purified from TIL cultures by flow cytometric cell sorting at day 54 using a mAb recognizing a framework epitope present on all ~/~ TCR. Positively sorted ~ T cells were expanded in CM containing IL-113 and IL-7 for at least (Fig. 2) . These ~/B+ TIL lines expressed a reproducibly similar pat- ) were isolated by cell sorting using the anti-pan-~/B rnAb5A6.E93, and cultured for 2 wk in AIM-V medium containing ILl~3/IL-7 (1,000 IU/ml) before phenotypic analysis by flow cytometry using mAbs recognizing 0tl3 or "78 T cell subsets. Positively sorted TIL stained for 98% of the cell population positive with an anti-pan-~/B TCR mAb or using the V81/J81/ J~2-specific mAb BTCS-1. The majority of cells expressed the V3'2 chain and stained negative for expression of the VB2 chain or the cel3 TCR. tern of reactivity using mAb specific for activation or adhesion molecules (summarized in `/8 + TIL lines were evaluated at three different times during in vitro culture for cytolytic reactivity against a panel of target cancer cell lines of diverse histological origin (compiled in Fig. 3 ). TIL release of IFN-`/in response to each target was also evaluated for the three `/8 TIL lines. 7-d LAK cells (PBL cultured in 1,000 IU/ml IL-2) served as control effector cells and efficiently lysed each target cell line (>45% lysis at an E/T of 30:1) with the exception of the colorectal cancer cell line HT29 (showing 10% specific lysis), y5 TIL lines lysed the NK target cell fine K562 poorly (in the range of 8-14% specific lysis) and failed to lyse a variety of the LAK/NK-sensitive target cell lines including Daudi, CIR, U937, Molt-4, and T2. EBV-transformed B cell targets, as well as mucin-expressing EBV + B cell lines (C1P,-Mucl, S-EBV-Mucl) were not lysed by `/g TIL. Examination of IFN-~ release by individual ~/8 TIL lines in response to these target cells revealed no significant increase in IFN-`/secretion compared with the constitutive release of IFN-`/ in the range of 37-40 pg/ml/ 16 h (Fig. 3) .
Of interest, "/8 TIL lines 1881, 3481, and 7279 lysed the colorectal cancer cell line 3481 (obtained from patient 3481) in addition to four different allogeneic colorectal cancer cell lines, with the exception of HT29. Examination of TIL release of IFN-`/in response to autologous (i.e., in the case of the matched -/8 TIL line 3481 and tumor line 3481) and allogeneic colorectal cancer cell lines revealed that all three `/~ TIL lines secreted IFN-`/ in response to autologous or allogeneic tumor cell fines (~<273 pg/ml/16 h), even in the absence of a significant cytolytic response (i.e., in the case of the target cell line HT29). These `/8 TIL lines did not lyse or secrete significant levels of IFN-% in response to diverse target cell lines, i.e., melanoma, one breast cancer, lung cancer, or autologous (obtained from patient 3481) or allogeneic fibroblasts. In contrast, ~/8 TIL lines 1881, 3481, and 7279 efficiently lysed two pancreatic cancer cell lines (pancreas89 and pancreasQGP-I), two renal cell cancer cell fines (P,.C1257 and R.CC1973), the norreal human intestine explant culture line (passage 1, CRL7136; ATCC), and to a lesser extent, the Wilms tumor cell fine SKNEP-1. However, these `/8 TIL did not lyse two additional squamous cell cancer cell lines (PCI-13 and PCI-50, data not shown). Target-specific release of IFN-`/release by V81 + T cells in response to these targets was not significant. Of note, despite some minimal cytotoxic `/~ TIL responses against K562, we could not detect significantly elevated IFN-`/secretion by ` (Fig. 4) . TIL 1881 and 3481 (cytotoxic) recognition of tumor 3481 was similarly inhibited by 35%. Addition of mAb directed against V52 did not affect T cell-mediated lysis. All three `/5 TIL lines showed a diminished cytotoxic T cell response ifpreincubated with antiserum specific for the fibronectin receptor (~<59% inhibition of specific lysis) but not with antiserum specific for the vitronectin receptor. ",/8 T cell-mediated lysis was inhibited by 80% by an Ab directed against the [32 integrin chain, and by ~<50% by a mAb directed against the [37 integrin chain, a component of the intraepithelial lymphocyte (IEL) marker. This was, however, not a uniform trend since the `/5 TIL line 3481 was only inhibited by ~10% by an Ab directed against CD103 (i.e., [37 chain Positive sorted ~/8 § T cells, analyzed by flow cytometry for expression of activation markers, exhibited a similar phenotype in three different experiments at various time points. Viable lymphocytes were gated based on size (FSC) and granularity (SSC) criteria, and data were collected for 5,000 cells as determined by forward light scatter intensity using Lysis II software on a FACScan | Results are reported as percent of cells staining positive for a given marker.
orectal cancer cell lines, pancreatic cancer, and renal cell cancer (Fig. 3) . However, these ~/B T cell effector cells also recognize (to comparably lesser extent) the erythroleukemia cell hne K562 and early passage cells derived from "normal n. intestine" (explant culture CRL7136, HS186.INT; ATCC). We performed cold target inhibition assays using the SlCrlabeled aUogeneic colorectal cancer cell line SW480 and a panel of nonlabeled target cell lines as competitive inhibitors in order to evaluate the commonality of hgands expressed on these target cells. Cold targets were admixed with 51Cr-labeled SW480 targets at 30:1, 10:1, and 3:1 (cold/hot target ratios) as indicated ( the D~2 segment (9/20); 2/20 cDNA clones used the D81 segment. Nucleotide sequences assigned to the D81 or the D82 regions were typically shorter, compared with segments used by D~3. N/P region nucleotides were remarkably long (~<29 bp in cDNA clone 1881-10). Fig. 7 depicts the predicted amino acid sequences encoded by each individual cDNA clone. We noted that in 6/20 TCR sequences (3' to the Dg3 segment, NP region), a hydrophobic aromatic tyrosine (Y), and in (different) 8/20 TCR sequences, a hydrophilic, aliphatic leucine (L) residue were encoded. The amino acid residue was in some cDNA clones generated by basepairs provided by the V region and the N/P region, and in other cDNA clones from basepairs in the N/P region alone, 3' to the V81 chain of the TCR. TCR Repertoire in Colorectal Cancer. The V81 + T cell population has been previously shown to represent the predominant T cell subset observed in normal human intestine (5-8). Since we did not have normal mucosa or PBL available from patients 1881, 3481, and 7279, we could not directly address whether the mRNA transcripts detected in "/~ TIL were also present in normal colonic mucosa adjacent to colon cancer or in PBL from these patients. The three "/8 TIL lines showed a preferential usage of the V"/2, V"/1.2, and V"/1.8 TCR segments (as determined by RT-PCR), which were also exclusively identified in the freshly collected tumor samples obtained from these patients, thereby exluding potential in vitro artefacts associated with preferential T cell subset expansion (data not shown). To test for TCP, V~/V"/usage in matched (primary) colon adenocarcinoma samples and in tumor-free (distal or proximal to the tumor) adjacent mucosa, we extracted RNA from freshly collected tumor/normal mucosa samples obtained from seven additional patients with primary colorectal cancer, mP, NA was reverse transcribed into cDNA and tested for TCP, "/or ~ transcripts by RT-PCR as described in Materials and Methods. Specific PCR products were validated by Southern blot analysis using internal primers for individual TCR ~/or 8 transcripts (data not shown). 5/7 adenocarcinoma samples exclusively expressed VM transcripts, whereas 2/7 adenocarcinoma samples showed additional V~2 transcripts, which were also found in 7/7 tumor proximal/distal normal mucosa samples (Table 3) . 2/7 adenocarcinoma samples exclusively expressed the TCP, '/1.2 and '/2 transcripts, and 2/7 cancer samples expressed additionally V~/1.8 transcripts (identical to the TCR ~ usage pattern in '/$ TIL lines described above). 3/7 cancer specimens expressed the same V'/ mRNA expression pattern and additionally expressed V'/3 mRNA. All seven normal (matched) mucosa specimens showed typical V81 and V82 mP, NA transcripts and predominantly V'/1.2, '/1.8, ~/2, "/3, and, in two specimens, V~1.4 mRNA, expression. In contrast, the matched adjacent tumor tissue revealed exclusive expression of V81 and V"/1.2, V"/1.8, and V"/2 mRNA (Table 3) . Restricted Vgl/V"/1.2, V"/1.8, V"/2 mRNA expression patterns were also obtained upon examination of 25 primary colorectal cancer specimens and 15 colon adenocarcinomas metastatic to liver (our unpublished observations).
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Note that s/20 cDNA clones exhibit the amino acid L in the N/P region 3' to the Vgl region and 6/20 cDNA clones exhibit the amino acid Y generated by the N/P region 3' to the D~3 segment. Sequence data are available from Genbank/EMBL/ DDBJ under accession numbers U30189-U30208.
Discussion
We have succcessfully expanded three individual colorectal cancer-derived ~/8 + T cell lines by in vitro culture using IL-113 and IL-7. This strategy was based on previous observations (39) that a combination of IL-113 and IL-7 promotes the preferential outgrowth of peritoneal ~8 T cells from Listeria monocytogenes-infected mice. IL-113 may act directly on ~/B + TCR-responsive T cells (39, 40) or IL-l[3-mediated effects may be attributed to initial IL-I[3-induced activation of dendritic cells, which have recently been shown to be involved in ~/B T cell activation and expansion (41) . The IL-113/IL-7-expanded TIL populations exhibited stable phenotype and functional characteristics for 4 mo in culture. This phenotypic stability may reflect an inherent characteristic of the ~/8 T cell subset examined, or may be due to IL-7-mediated effects that have been reported to sustain Ag-specific (CD4 § 0t[3 T cells) in the absence of antigenic restimulation for ~<22 mo (42) . Cytokine-mediated effects on cell surface expression of adhesion molecules has been well documented for human NK cells that exhibit differential expression of CDlla-c, and VLA1-6 cell upon IL-2 stimulation (43). Alternatively, the similar pattern of adhesion molecule expression in ~/B T cell lines derived from three individual patients may reflect a tissue-specific (i.e., intestinal) phenomenon. For example, y8 T cells isolated from intestinal lymph nodes and Peyer's patches appear to express varied levels of CD44 or B7 molecules that impact their tissue-biased homing pattern (44) . Synovial fluid VB1 + T cells from patients with juvenile rheumatoid arthritis express predominantly the early activation marker CD69 and the high molecular isoform of the CD45 (CD45RA) (45) , a pattern that we similarly observed for IL-7-expanded ~/B T cells in this report.
The bulk ~/B TIL population obtained from three individual patients showed exclusive expression of the V'81 TCR and preferential coexpression of the V~/2 TCR. Additional TCR ~/transcripts, including those for the V~/1.2 and the Vyl. mRNA was extracted from freshly resected (primary) colorectal cancer specimens and from tumor-free adjacent mucosa harvested 3 cm proximal or distal to the tumor lesions. RNA was reverse transcribed into cDNA and tested for V~/VB TCR-specific mRNA transcripts in individual samples by RT-PCR using a primer panel as described in Materials and Methods. Identity of PCR products was confirmed by using V~-or VB-specific V-region TCR internal oligonucleotides by Southern blot analysis (data not shown).
TCR (33, 34) , a finding that has been corroborated for ~8 T cell clones obtained from a patient with renal cell cancer (35) . In this latter study, the majority of V81 + T cell clones preferentially recognized the autologous renal cell cancer, but additional V81 + T cell clones from this patient also lysed allogeneic renal cell cancer hnes (35) . V81 + T cells have also been identified in a variety of human diseases that are thought to have an "autoimmune" etiology (26) (27) (28) (29) (30) (31) , and have also been identified in increased numbers in Wilms tumors (47) and in the hver of tumor-bearing hosts (48) . The V81 + TIL lines generated in our study lyse colorectal, renal cell, and pancreatic cancer cell hnes, an early passage line of human normal intestine (CRL7136, HS186.INT; ATCC), and to a lesser extent the erythroleukemia cell line K562. Our results confirm previous observations that V81+/V~2 (or "/9) + T cells typically do not lyse Daudi targets. Whereas such (V81+V~/2 +) T cells may recognize an Ag expressed on Burkitt's lymphoma cell lines (49) , this specificity does not appear to be relevant in our study. Based on cold target inhibition assays, our ~/8 TIL lines appear to exhibit similar specificities and to recognize common target structures expressed by epithelial target cell lines and freshly explanted/cultured intestinal tissue ( [54] and renal cell cancer [53] ) supports the concept that antitumor cellular immunity, in fact, represents an autoimmune response, a finding that may be equally apphcable to antitumor-reactive ~/8 T cells. CD1 has been reported to be expressed by intestinal cells (14, 55) and may serve as a potential target structure for certain ~/8 T cells. In mice, the nonclassical Tla Ag, also expressed in the intestine (15) , may be recognized by CD8 § intestinal Vy5 + T cells (15, 16) . mAbs directed against MHC class I (w6/32) or II DR (mAb L243), or mAbs recognizing CDla or CDlc were not able to block ~/8 T cellmediated cytotoxicity of target cell lines (data not shown).
Whereas this suggests that ~/8 + T cell recognition of autologous or allogeneic cancer cell lines is not restricted by MHC class I or II, the inability ofanti-CD1 mAbs to block ~,t8 T cell reactivity may not be informative because of inefficient blocking of relevant determinants. Examination of target cell surface expression ofCD1 Ags revealed that only the cell line Molt-4, not recognized by V81 + T cells, stained positive for CD1 (data not shown).
Murine V~/3 + T cells (dendritic epidermal T cells) specifically recognize keratinocytes (56) . It is possible that human V81 + T cells recognize cells of epithelial origin in a tissue-specific fashion and react against target structures induced by stress (i.e., in vitro culture) and/or by malignant transformation. Potential candidates for target Ags may represent HSPs (13, 19, 20, 57) . Anti-breast-cancer directed y8 T cell responses are augmented by transfecting breast tumor cells with the 27-kD HSP protein (58), suggesting a role for HSP expression in ~/8 T cell recognition of solid tumors. A strong correlation between cell surface expression of liSP 72 and the 67-kD high affinity laminin receptor in human lung cancer and the outgrowth ofantitumordirected cytotoxic ~/8 T cells (59) has also been noted, grp 75 has also been suggested to present tumor-specific Ags (presumably in the form ofpeptides) to ~/8 T cells (57) . However, we were unable to inhibit T cell reactivity with a panel of anti-HSP Abs, a finding that either supports the lack of involvement of the specific Ag in ~/8 T cell-mediated reactivity or reflects the inability of a given mAb to block a functional epitope present on the indicated HSP (data not shown ). To correlate HSP expression on individual target cells with cytolytic ~/8 + T cell reactivity or specific IFN-~/ release, we examined target cell surface expresssion of several well-characterized HSP subsets (including HSP 60, 68, 70, 72, 73, and 75; see Table 1 ) by flow cytometry. In summary, all target cell lines tested negative for HSP 60, 68, 70, and 75 expression and showed variable cell surface staining using mAbs directed against HSP 72 or 73 comparably high expression of HSP 72 or 73 (our unpublished observations). Target cell lines exhibiting comparably high expression of liSP 72 or 73 (e.g., Daudi, or I 937) were not recognized by ",t8 T cells (Fig. 3) . In contrast, the human explant culture CRL7136, HS185.INT from norreal human intestine lacked HSP 72/73 cell surface expression, but provided target structures recognized by ~/8 T cells. Based on these data, we could not identify a positive correlation of liSP 72 and 73 cell surface expression and ~/8 T cell recognition. However, the cell surface density of individual HSP subsets relevant for ~/8 T cell recognition, as well as potential peptides presented by such alternate Agpresenting molecules, are poorly defined. A more detailed examination of individual intracellular and cell surface family HSP protein expression in targets recognized by human intestinal ~8 T cells may aid clarification of the role of HSPs as candidate target structures.
Of note, four mAbs were able to partially block ~5 T cell recognition of sensitive target cells: Abs directed against the TCR, against the [32 or [37 integrin chains, or an Ab against the HFR receptor. Cellular interactions with fibro-nectin have been shown to induce phosphorylation of a 120-kD protein on T cells and HFP,.-mediated "costimulation" may augment T cell cytotoxicity induced by TCR stimulation (60) . Fibronectin-associated T cell stimulation may therefore facilitate TCR restricted effector cell functions (e.g., granzyme release), or it may lower the signal threshold required for optimal T cell stimulation (60, 61) . Blockade of the fibronectin receptor on ~ T cells may therefore interfere with ~/~ T cell stimulation. Fibronectin also appears to be involved in ot4/137-mediated adhesion of T cells to the vascular cell adhesion molecule 1 (VCAM-1), or to mucosal addressin cell adhesion molecule 1 (MADCAM-1) (62) . Interaction of 137 with fibronectin, MADCAM-1, and VCAM-1 involves different, functionally distinct determinants on the 137 integrin molecule (62) . Inhibition of cytotoxic y5 T cell responses with an Ab directed against the 137 integrin chain may reflect the importance of 137 integrin hgands (i.e., MADCAM, fibronectin, etc.) expressed by tumor cells of epithehal origin.
It should be noted that differences in ~/~ T cell responses to individual targets as measured by cytotoxicity and IFN-y release may be attributed to the presence of more than one discrete effector T cell population as defined by differential cell surface expression of CD8 and CD4 (Fig. 2) . CD8 appears to be preferentially expressed on V~I § T cells, predominantly in the form of a CD8 ot chain homodimer, which has been shown to be inducible by various cytokines (e.g., IL-4; 63-65). The effects oflL-113 or IL-7 cell surface expression on CD8 chains has not been evaluated to this end and awaits further clarification. CD8 acts as an adhesion molecule for et13 TCR + T cells and as a signal-transducing molecule. The function of CD8 on intestinal "y~ T cells remains elusive, since: (a) CD8 expression appears to be rapidly induced after tissue homing, suggesting that CD8 expression may not be correlated with conventional Ag-driven activation occurring in MHC class I-restricted ot13 + T cells (66) ; and (b) target cell recognition by V~I + T cell clones appears not to be affected by CD8 blockade (67) . Additionally, direct cloning of freshly isolated CD4 + TCP, y~+ T cells indicated that VS1 + T cells may also express CD4 in vivo. It is interesting to note that such CD4 + ~/~ T cells have been characterized to lack cytolytic functions, but to secrete high levels of cytokines (65) . These data may suggest that variations in ~/g T cells responses (e.g., different levels of inhibition of target cell lysis using mAbs directed against the ",/8 TC1L; Fig. 4 ) may reflect the presence of such distinct ~/8 T cell subpopulations defined by CD8 and CD4 expression, correlating with different (i.e., cytotoxicity and cytokine release) T cell effector functions.
Partial inhibition of target cell recognition by Abs directed against the ~/8 TCR, indicates that cytolytic V81 + T cell responses are mediated by specific target cell recognition involving the TCR. Potential ligands for ~/5 TCR recognition may represent native target cell surface structures (11, 12, 17, 19, 20, 21, 68) , consolidating the notion that the ~/8 T ceil population may use a fundamentally different method of target cell recognition as compared with that of the MHC-restricted or13 T cell population. Significant IFN-~ release by three ~/~ TIL hnes derived from colon cancer patients in response to autologous or allogeneic colon cancer cell lines suggests that these ~/~ T cells may be therapeutically important. "/8 T cells may therefore not only be useful as effector T cell subsets capable of directly eradicating cancer cells when adoptively transferred into cancer patients, but they also may be useful in creating a "Thl-hke" cytokine milieu within the tumor lesion microenvironment. IFN-~/ may act directly on tumor cells e.g., by, for example, increasing cellularly expressed MHC products, which serve as restricting molecules for MHCpresented peptides capable of being recognized by ot13 + T cells. IFN-~/ release in response to cancer may be particularly important in the case where tumor cells display resistance to perforin-mediated lysis (e.g., HT29; Fig. 3 ), which may reflect tumor cell overexpression ofCD59, a molecule capable of preventing perforin complex formation into lytic structures on the target cell surface (69) . The intimate interaction of~/~ and cx13 T cells has previously been documented and it is envisioned that y~+ T cells may impact significantly upon the quality and magnitude of 0t13 T cellmediated immune responses (70--74) .
In summary, our results demonstrate that ~/~ TIL hnes obtained from colon cancer recognize target structures expressed by colon, pancreatic, and by renal cell cancer cells in a MHC-unrestricted manner. This particular recognition pattern is shared by ~/~ TIL lines obtained from three different patients, indicating that the prevalent VS1 + TCR subpopulation may play a role in anti-tumor-directed immunity. Examination of a limited number of TCR transcripts from colon cancer-derived ~/~ T cell populations expanded in vitro supports the preferential usage of the V~1/D83/J81 TCR segments that have been reported to represent common ~/8 TCR transcripts observed in colon biopsies harvested from normal healthy individuals (5) (6) (7) (8) . The junctional TCR sequences in ~/8 TIL appear to be diverse, although there was some common usage of certain amino acid residues in the N/P regions shared by individual cDNA clones. We believe that the exclusive use of TC1L V81 does not reflect a preferential homing receptor for human intestinal ~ T cells, but rather reflects the inherent useful nature of this particular VDJ recombination in TCR reactive against certain Ags expressed by stressed intestinal cells or by epithehal cancer cells.
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